US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

登録

ホーム
投資
株式
アメリカ
NASDAQ
Arcutis Biotherapeutics Inc (ARQT)
Arcutis Biotherapeutics Inc (ARQT) ニュース

ARQT

Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ARQT

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/30	08 : 38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/05/29	04 : 54	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/05/28	20 : 00	PR Newswire (Canada)	Arcutis Canada annonce l'acceptation aux fins d'examen par Santé Canada de la présentation de la crème de roflumilast à 0,15 % pour le traitement de la dermatite atopique chez les adultes et les enfants âgés de 6 ans et plus	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/05/21	06 : 12	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/05/18	04 : 58	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/05/15	05 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/05/15	05 : 00	GlobeNewswire Inc.	Arcutis Announces First Quarter 2024 Financial Results and Provides Business Update	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/05/14	20 : 18	IH Market News	US Futures Remain Steady Amid Wall Street Caution Ahead of April PPI Report	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/05/13	21 : 00	GlobeNewswire Inc.	Expert Panel Review Further Validates Use of ZORYVE® (roflumilast) Topical Foam, 0.3% for Treatment of Seborrheic Dermatitis Across Diverse Hair Types Published in Journal of Clinical and Aesthetic Dermatology	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/05/04	05 : 00	GlobeNewswire Inc.	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/04/30	05 : 00	GlobeNewswire Inc.	Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/04/10	21 : 00	GlobeNewswire Inc.	Arcutis Appoints David Topper as Chief Financial Officer	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/04/06	05 : 00	GlobeNewswire Inc.	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/04/01	20 : 00	GlobeNewswire Inc.	Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/28	21 : 00	GlobeNewswire Inc.	Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/11	21 : 00	GlobeNewswire Inc.	Arcutis Promotes Todd Tucker to Chief Human Resources Officer	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/11	05 : 00	GlobeNewswire Inc.	Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/10	06 : 00	GlobeNewswire Inc.	New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/07	07 : 14	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/07	07 : 09	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/07	07 : 08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/06	06 : 00	GlobeNewswire Inc.	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/05	07 : 47	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/05	07 : 42	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/05	07 : 40	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/05	06 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/05	06 : 00	GlobeNewswire Inc.	Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/04	22 : 00	GlobeNewswire Inc.	Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/02	06 : 11	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ARQT	Arcutis Biotherapeutics Inc
2024/03/02	06 : 06	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:ARQT	Arcutis Biotherapeutics Inc

Showing the most relevant articles for your search:NASDAQ:ARQT

1 2 3 4 5 6 7 8 9 10 次へ >>

MGLUB60 Ex:59,9

NLBNPIT1ZN48 20241220 10

BNP Paribas Fintro 1.1% ...

Intesa Sanpaolo

Virtue Player Points

Covivio Fonciere des Reg...

NLBNPIT1VU84 20351221 8....

Brussels City bond 0.829...

Hsbc Bank Usa Na Capped ...

Invesco Markets

Banca Cesare Ponti

Bei Fx 2.75% Jul29 Eur

Vanguard Investments Aus...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約